Biomedicine & Pharmacotherapy
From January 2019 Biomedicine and Pharmacotherapy will become an open access journal. Authors who publish in Biomedicine and Pharmacotherapy will be able make their work immediately, permanently, and freely accessible. Biomedicine and Pharmacotherapy authors will pay an article publishing charge (APC), have a choice of license options, and retain copyright to their published work.
Biomedicine and Pharmacotherapy continues with the same aims and scope, editorial team, submission system and rigorous peer review.
Biomedicine and Pharmacotherapy authors will pay an article publishing charge (APC), have a choice of license options, and retain copyright to their published work. The APC will be requested after peer review and acceptance and will be required for all accepted articles submitted after 15 October 2018. The APC for Biomedicine and Pharmacotherapy is US$ 2800 (excluding taxes).Please note: Authors who have submitted papers before 15 October 2018 will have their accepted paper published in Biomedicine and Pharmacotherapy at no charge. Authors submitting papers after this date will be requested to pay the APC.
The general fields of interest will include Cancer, Nutriceutics, Neurodegenerative, Cardiac and Infectious Diseases.Special emphasis will be placed on studies of specific topics such as molecular mechanisms, gene regulation in normal and pathologic cells as well as susceptibility in response to oncogenic agents. Effects of drugs on preclinical and clinical pharmacology and the role of bacteria, viruses and parasites in animals and humans.Brief reports of meetings, symposia and conferences will also be considered for publication as well as brief listings of scientific meetings or academic courses of interest to the readers
Editor-in-Chief: D.M. Townsend
- Imprint: ELSEVIER
- ISSN: 0753-3322